Published in Front Immunol on May 14, 2013
Treatment with Vitamin D/MOG Association Suppresses Experimental Autoimmune Encephalomyelitis. PLoS One (2015) 1.43
It's time to bring dendritic cell therapy to type 1 diabetes. Diabetes (2014) 0.85
Dendritic cell-based approaches for therapeutic immune regulation in solid-organ transplantation. J Transplant (2013) 0.85
Vitamin D controls murine and human plasmacytoid dendritic cell function. J Invest Dermatol (2013) 0.84
Tolerogenic dendritic cells and their applications in transplantation. Cell Mol Immunol (2014) 0.84
The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape. Front Immunol (2013) 0.83
Vitamin D immunoregulation through dendritic cells. Immunology (2016) 0.83
Vitamin D regulates cytokine patterns secreted by dendritic cells to promote differentiation of IL-22-producing T cells. PLoS One (2015) 0.82
Generation of Tolerogenic Dendritic Cells and Their Therapeutic Applications. Immune Netw (2016) 0.80
Tissue specific heterogeneity in effector immune cell response. Front Immunol (2013) 0.79
Apoptotic cell-treated dendritic cells induce immune tolerance by specifically inhibiting development of CD4(+) effector memory T cells. Immunol Res (2016) 0.78
Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients. J Neuroinflammation (2016) 0.78
Metabolism Is Central to Tolerogenic Dendritic Cell Function. Mediators Inflamm (2016) 0.77
Diversity of immune cell types in multiple sclerosis and its animal model: Pathological and therapeutic implications. J Neurosci Res (2017) 0.77
Dendritic cell metabolism: immunity and tolerance. Oncotarget (2015) 0.75
Autologous tolerogenic dendritic cells derived from monocytes of systemic lupus erythematosus patients and healthy donors show a stable and immunosuppressive phenotype. Immunology (2017) 0.75
Differential transcriptome of tolerogenic versus inflammatory dendritic cells points to modulated T1D genetic risk and enriched immune regulation. Genes Immun (2017) 0.75
Toll-like receptors and innate immunity. Nat Rev Immunol (2001) 16.50
Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science (2003) 14.04
Tolerogenic dendritic cells. Annu Rev Immunol (2001) 13.77
The B7 family revisited. Annu Rev Immunol (2005) 13.51
How regulatory T cells work. Nat Rev Immunol (2008) 11.66
A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature (1997) 10.14
Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature (2008) 9.32
Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol (2009) 8.67
Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem (1999) 7.81
Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem (2002) 6.16
Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell (2004) 5.50
Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol (2002) 5.48
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
Induction of tolerance by IL-10-treated dendritic cells. J Immunol (1997) 4.65
Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol (2002) 4.64
T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today (1999) 4.49
Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med (2002) 4.37
Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28
Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med (2002) 4.18
Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med (2010) 4.17
Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med (2003) 3.89
Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med (2010) 3.84
Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med (2002) 3.80
IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol (2010) 3.43
Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J Exp Med (2009) 3.38
Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J Clin Invest (2006) 3.31
The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol (2003) 3.18
Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev (2003) 3.15
Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med (2009) 3.13
Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells. J Immunol (2004) 3.13
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med (2011) 2.69
CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J Immunol (2008) 2.69
A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization. J Biol Chem (2002) 2.61
Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev (2010) 2.55
Tolerogenic dendritic cells: cytokine modulation comes of age. Blood (2006) 2.51
Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci (2003) 2.36
Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nat Med (2009) 2.30
Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci U S A (2009) 2.22
Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A (2001) 2.14
Plasmacytoid dendritic cells are crucial for the initiation of inflammation and T cell immunity in vivo. Immunity (2011) 2.12
Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol (2000) 2.10
Lack of conventional dendritic cells is compatible with normal development and T cell homeostasis, but causes myeloid proliferative syndrome. Immunity (2008) 2.04
Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol (2008) 1.88
Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. J Exp Med (2012) 1.81
Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat (2009) 1.80
Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum (2001) 1.77
Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol (2009) 1.76
1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol (2007) 1.69
Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation. Immunol Rev (2010) 1.68
Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care (2011) 1.65
Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol (1999) 1.65
TNF-alpha is critical for antitumor but not antiviral T cell immunity in mice. J Clin Invest (2007) 1.63
ICOS controls the pool size of effector-memory and regulatory T cells. J Immunol (2008) 1.62
The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res (1999) 1.61
DC subsets in positive and negative regulation of immunity. Immunol Rev (2010) 1.56
GM-CSF-dependent, CD103+ dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization. J Exp Med (2010) 1.52
De novo induction of antigen-specific CD4+CD25+Foxp3+ regulatory T cells in vivo following systemic antigen administration accompanied by blockade of mTOR. J Leukoc Biol (2008) 1.52
Chemokine receptor CXCR3 facilitates CD8(+) T cell differentiation into short-lived effector cells leading to memory degeneration. J Exp Med (2011) 1.41
Cutting edge: expression of XCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8α+ type. J Immunol (2011) 1.39
TGF-beta is required to maintain the pool of immature Langerhans cells in the epidermis. J Immunol (2010) 1.39
Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin Exp Immunol (2010) 1.38
Effects of aryl hydrocarbon receptor signaling on the modulation of TH1/TH2 balance. J Immunol (2005) 1.38
Differential expression of Toll-like receptor (TLR)-2 and TLR-4 on monocytes in human sepsis. Clin Exp Immunol (2004) 1.34
Anergic T cells inhibit the antigen-presenting function of dendritic cells. J Immunol (2000) 1.32
Tumor necrosis factor alpha in the pathogenesis of cerebral malaria. Cell Mol Life Sci (2003) 1.29
Role of dendritic cells in the induction of regulatory T cells. Cell Biosci (2011) 1.27
Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases. J Cell Biochem (2003) 1.26
Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res (2012) 1.25
Vaccines and the future of human immunology. Immunity (2010) 1.24
Dexamethasone inhibits dendritic cell maturation by redirecting differentiation of a subset of cells. J Leukoc Biol (1999) 1.20
Dendritic cells: arbiters of immunity and immunological tolerance. Cold Spring Harb Perspect Biol (2012) 1.20
ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells. Eur J Immunol (2002) 1.19
Dendritic cells ameliorate autoimmunity in the CNS by controlling the homeostasis of PD-1 receptor(+) regulatory T cells. Immunity (2012) 1.17
An anti-inflammatory role for plasmacytoid dendritic cells in allergic airway inflammation. J Immunol (2009) 1.17
Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J Immunol (2004) 1.16
Increased CD127 expression on activated FOXP3+CD4+ regulatory T cells. Eur J Immunol (2010) 1.16
Dendritic cells and macrophages are essential for the retention of lymphocytes in (peri)-insulitis of the nonobese diabetic mouse: a phagocyte depletion study. Lab Invest (2005) 1.15
Redirection of human autoreactive T-cells Upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). Diabetes (2002) 1.13
The vitamin D analog, TX527, promotes a human CD4+CD25highCD127low regulatory T cell profile and induces a migratory signature specific for homing to sites of inflammation. J Immunol (2010) 1.12
Comparative study of clinical grade human tolerogenic dendritic cells. J Transl Med (2011) 1.12
IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo. Proc Natl Acad Sci U S A (2011) 1.10
Differential protein pathways in 1,25-dihydroxyvitamin d(3) and dexamethasone modulated tolerogenic human dendritic cells. J Proteome Res (2011) 1.09
Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. Blood (2000) 1.07
Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. J Immunother (2003) 1.04
Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J Immunol (2010) 1.03
Dendritic cells as killers: mechanistic aspects and potential roles. J Immunol (2008) 0.99
1alpha,25-dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. J Autoimmun (2004) 0.99
Immunoregulatory molecules are master regulators of inflammation during the immune response. FEBS Lett (2012) 0.98
Wnt5a skews dendritic cell differentiation to an unconventional phenotype with tolerogenic features. J Immunol (2011) 0.97
1,25-Dihydroxyvitamin D3 alters murine dendritic cell behaviour in vitro and in vivo. Diabetes Metab Res Rev (2011) 0.96
Gata1 regulates dendritic-cell development and survival. Blood (2007) 0.95
A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol (2011) 0.94
TLR triggering on tolerogenic dendritic cells results in TLR2 up-regulation and a reduced proinflammatory immune program. J Immunol (2009) 0.94
Pathogen sensors and chemokine receptors in dendritic cell subsets. Vaccine (2012) 0.94
Plasmacytoid dendritic cells in autoimmune diabetes - potential tools for immunotherapy. Immunobiology (2009) 0.92
Homing of human autoreactive T cells into pancreatic tissue of NOD-scid mice. Diabetologia (2004) 0.92
Dexamethasone/1alpha-25-dihydroxyvitamin D3-treated dendritic cells suppress colitis in the SCID T-cell transfer model. Immunology (2008) 0.90
Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. Clin Exp Immunol (2012) 0.90
A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy. J Allergy Clin Immunol (2012) 0.89
Development of type 1 diabetes in a patient treated with anti-TNF-alpha therapy for active rheumatoid arthritis. Diabetologia (2009) 0.88
Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes (2005) 4.34
Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest (2004) 3.17
Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A (2007) 3.11
CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest (2008) 3.11
Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. Am J Hum Genet (2007) 2.89
Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med (2012) 2.86
Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes. Proc Natl Acad Sci U S A (2005) 2.70
Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. Gastroenterology (2005) 2.30
Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers. Diabetes (2010) 1.91
Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol (2009) 1.76
Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One (2008) 1.67
Current advances and travails in islet transplantation. Diabetes (2009) 1.63
KIR in type 1 diabetes: disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes (2003) 1.42
The vitamin D receptor gene FokI polymorphism: functional impact on the immune system. Eur J Immunol (2007) 1.28
Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients. Diabetes (2009) 1.27
Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop. J Autoimmun (2003) 1.25
Analysis of a functional BTNL2 polymorphism in type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. Hum Immunol (2006) 1.24
HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol (2004) 1.23
Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol (2011) 1.21
Mannose-binding lectin: clinical implications for infection, transplantation, and autoimmunity. Hum Immunol (2006) 1.20
Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression. Diabetes (2010) 1.18
The TRAF1-C5 region on chromosome 9q33 is associated with multiple autoimmune diseases. Ann Rheum Dis (2009) 1.17
Posttranslational modification of HLA-DQ binding islet autoantigens in type 1 diabetes. Diabetes (2013) 1.16
Association of IL-1ra and adiponectin with C-peptide and remission in patients with type 1 diabetes. Diabetes (2008) 1.13
Redirection of human autoreactive T-cells Upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). Diabetes (2002) 1.13
A mini meta-analysis of studies on CD4+CD25+ T cells in human type 1 diabetes: report of the Immunology of Diabetes Society T Cell Workshop. Ann N Y Acad Sci (2006) 1.11
Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation. J Immunol (2011) 1.10
Differential protein pathways in 1,25-dihydroxyvitamin d(3) and dexamethasone modulated tolerogenic human dendritic cells. J Proteome Res (2011) 1.09
Islet-specific CTL cloned from a type 1 diabetes patient cause beta-cell destruction after engraftment into HLA-A2 transgenic NOD/scid/IL2RG null mice. PLoS One (2012) 1.07
CTLA4 is differentially associated with autoimmune diseases in the Dutch population. Hum Genet (2005) 1.06
DRB1*0401-restricted human T cell clone specific for the major proinsulin73-90 epitope expresses a down-regulatory T helper 2 phenotype. Proc Natl Acad Sci U S A (2006) 1.04
Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J Immunol (2010) 1.03
Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. J Autoimmun (2011) 1.00
Enhancing the sensitivity of assays to detect T cell reactivity: the effect of cell separation and cryopreservation media. Ann N Y Acad Sci (2004) 0.99
1alpha,25-dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. J Autoimmun (2004) 0.99
Precursor frequencies of T-cells reactive to insulin in recent onset type 1 diabetes mellitus. J Autoimmun (2004) 0.98
Association analysis of functional variants of the FcgRIIa and FcgRIIIa genes with type 1 diabetes, celiac disease and rheumatoid arthritis. Hum Mol Genet (2007) 0.97
Elevated levels of mannose-binding lectin at clinical manifestation of type 1 diabetes in juveniles. Diabetes (2005) 0.96
Islet antigen specific IL-10+ immune responses but not CD4+CD25+FoxP3+ cells at diagnosis predict glycemic control in type 1 diabetes. Clin Immunol (2008) 0.96
Processing and presentation of the islet autoantigen GAD by vascular endothelial cells promotes transmigration of autoreactive T-cells. Diabetes (2003) 0.95
Gluten-specific T cells cross-react between HLA-DQ8 and the HLA-DQ2α/DQ8β transdimer. J Immunol (2011) 0.95
Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev (2007) 0.95
TLR triggering on tolerogenic dendritic cells results in TLR2 up-regulation and a reduced proinflammatory immune program. J Immunol (2009) 0.94
Type 1 diabetes-associated HLA-DQ8 transdimer accommodates a unique peptide repertoire. J Biol Chem (2011) 0.94
Detection of autoreactive T cells in type 1 diabetes using coded autoantigens and an immunoglobulin-free cytokine ELISPOT assay: report from the fourth immunology of diabetes society T cell workshop. Ann N Y Acad Sci (2004) 0.92
Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients. Diabetes Care (2006) 0.91
Notch controls generation and function of human effector CD8+ T cells. Blood (2013) 0.90
Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients. Transplantation (2005) 0.88
HLA class I epitope discovery in type 1 diabetes: independent and reproducible identification of proinsulin epitopes of CD8 T cells--report of the IDS T Cell Workshop Committee. Ann N Y Acad Sci (2006) 0.88
Susceptibility loci for complex regional pain syndrome. Pain (2003) 0.88
Cross-reactive mycobacterial and self hsp60 epitope recognition in I-A(g7) expressing NOD, NOD-asp and Biozzi AB/H mice. J Autoimmun (2002) 0.88
Enhanced concentrations of interleukin 16 are associated with joint destruction in patients with rheumatoid arthritis. J Rheumatol (2004) 0.87
HLA-B8 in patients with the Lambert-Eaton myasthenic syndrome reduces likelihood of associated small cell lung carcinoma. Ann N Y Acad Sci (2003) 0.87
Tolerogenic dendritic cells impede priming of naïve CD8⁺ T cells and deplete memory CD8⁺ T cells. Eur J Immunol (2012) 0.86
HLA-DQ-regulated T-cell responses to islet cell autoantigens insulin and GAD65. Diabetes (2004) 0.86
Transfer of regulatory properties from tolerogenic to proinflammatory dendritic cells via induced autoreactive regulatory T cells. J Immunol (2011) 0.84
MICA marks additional risk factors for Type 1 diabetes on extended HLA haplotypes: an association and meta-analysis. Mol Immunol (2007) 0.84
Alcohol facilitates CD1d loading, subsequent activation of NKT cells, and reduces the incidence of diabetes in NOD mice. PLoS One (2011) 0.83
Changing faces, unmasking the beta-cell: post-translational modification of antigens in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes (2013) 0.82
Pretransplantation GAD-autoantibody status to guide prophylactic antibody induction therapy in simultaneous pancreas and kidney transplantation. Transplantation (2013) 0.82
Infectious tolerance as candidate therapy for type 1 diabetes: transfer of immunoregulatory properties from human regulatory T cells to other T cells and proinflammatory dendritic cells. Crit Rev Immunol (2013) 0.81
Diabetes: missing links. Nature (2007) 0.81
Genetically engineered human islets protected from CD8-mediated autoimmune destruction in vivo. Mol Ther (2013) 0.81
Biomarkers for immune intervention trials in type 1 diabetes. Clin Immunol (2013) 0.80
Beta cells under attack: toward a better understanding of type 1 diabetes immunopathology. Semin Immunopathol (2010) 0.80
IGF1 promoter polymorphism and cranial growth in individuals born very preterm. Horm Res Paediatr (2011) 0.79
Local autoantigen expression as essential gatekeeper of memory T-cell recruitment to islet grafts in diabetic hosts. Diabetes (2012) 0.79
Adenoviral vectors stimulate glucagon transcription in human mesenchymal stem cells expressing pancreatic transcription factors. PLoS One (2012) 0.79
Impact of disease heterogeneity on treatment efficacy of immunotherapy in Type 1 diabetes: different shades of gray. Immunotherapy (2015) 0.78
Predictive factors of allosensitization after immunosuppressant withdrawal in recipients of long-term cultured islet cell grafts. Transplantation (2013) 0.78
Innate and adaptive immunity to human beta cell lines: implications for beta cell therapy. Diabetologia (2016) 0.78
Alternative splicing and differential expression of the islet autoantigen IGRP between pancreas and thymus contributes to immunogenicity of pancreatic islets but not diabetogenicity in humans. Diabetologia (2013) 0.78
Targeting proinsulin-reactive CD8+ T cells: a new direction for type 1 diabetes treatment. Expert Rev Clin Immunol (2013) 0.78
T-cell assays to determine disease activity and clinical efficacy of immune therapy in type 1 diabetes. Am J Ther (2005) 0.78
Association analysis of myosin IXB and type 1 diabetes. Hum Immunol (2010) 0.78
Graves hyperthyroidism after stopping immunosuppressive therapy in type 1 diabetic Islet cell recipients with pretransplant TPO autoantibodies. Diabetes Care (2009) 0.78
Seasonality of birth in patients with type 1 diabetes. Lancet (2002) 0.78
The association between autoimmune thyroiditis, autoimmune gastritis and type 1 diabetes. Pediatr Endocrinol Rev (2003) 0.77
HLA incompatibility and immunogenicity of human pancreatic islet preparations cocultured with blood cells of healthy donors. Hum Immunol (2005) 0.77
Challenges in developing endpoints for type 1 diabetes intervention studies. Diabetes Metab Res Rev (2009) 0.76
Self-glycolipids modulate dendritic cells changing the cytokine profiles of committed autoreactive T cells. PLoS One (2012) 0.75
Preservation of recall immunity in anti-CD3-treated recent onset type 1 diabetes patients. Diabetes Metab Res Rev (2011) 0.75
[Immunotherapy for type 1 diabetes mellitus (DM1)]. Ned Tijdschr Geneeskd (2012) 0.75
Identification of donor origin and condition of transplanted islets in situ in the liver of a type 1 diabetic recipient. Cell Transplant (2016) 0.75